Literature DB >> 11283797

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

S A Rasmussen1, Q Yang, J M Friedman.   

Abstract

Although neurofibromatosis 1 (NF1) is a relatively common autosomal dominant condition, information about its effect on mortality is limited. We used Multiple-Cause Mortality Files, compiled from U.S. death certificates by the National Center for Health Statistics, for 1983 through 1997. We identified 3,770 cases of presumed NF1 among 32,722,122 deaths in the United States, a frequency of 1/8,700, which is one-third to one-half the estimated prevalence. Mean and median ages at death for persons with NF1 were 54.4 and 59 years, respectively, compared with 70.1 and 74 years in the general population. Results of proportionate mortality ratio (PMR) analyses showed that persons with NF1 were 34 times more likely (PMR=34.3, 95% confidence interval [CI] 30.8-38.0) to have a malignant connective or other soft-tissue neoplasm listed on their death certificates than were persons without NF1. Overall, persons with NF1 were 1.2 times more likely than expected (PMR=1.21, 95% CI 1.14-1.28) to have a malignant neoplasm listed on their death certificates, but the PMR was 6.07 (95% CI 4.88-7.45) for persons who died at 10-19 years of age and was 4.93 (95% CI 4.14-5.82) for those who died at 20-29 years of age. Similarly, vascular disease was recorded more often than expected on death certificates of persons with NF1 who died at <30 years of age (PMR=3.26, 95% CI 1.31-6.71 at age <10 years; PMR=2.68, 95% CI 1.38-4.68 at age 10-19 years; and PMR=2.25, 95% CI 1.46-3.32 at 20-29 years) but not in older persons. This study supports previous findings of decreased life expectancy for persons with NF1 and, within the limitations of death certificates, provides population-based data about NF1 morbidity and mortality that are useful to clinicians caring for patients with NF1.

Entities:  

Mesh:

Year:  2001        PMID: 11283797      PMCID: PMC1226092          DOI: 10.1086/320121

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland.

Authors:  M Poyhonen; S Kytölä; J Leisti
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

Review 2.  NF1 gene and neurofibromatosis 1.

Authors:  S A Rasmussen; J M Friedman
Journal:  Am J Epidemiol       Date:  2000-01-01       Impact factor: 4.897

3.  Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms.

Authors:  S A Sørensen; J J Mulvihill; A Nielsen
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

4.  A comparison of standardized and proportional mortality ratios.

Authors:  E Roman; V Beral; H Inskip; M McDowall; A Adelstein
Journal:  Stat Med       Date:  1984 Jan-Mar       Impact factor: 2.373

5.  On the utility of proportional mortality analysis.

Authors:  L L Kupper; A J McMichael; M J Symons; B M Most
Journal:  J Chronic Dis       Date:  1978-01

6.  Comparison of the proportionate mortality ratio and standardized mortality ratio risk measures.

Authors:  P Decouflé; T L Thomas; L W Pickle
Journal:  Am J Epidemiol       Date:  1980-03       Impact factor: 4.897

7.  An alternative to the proportionate mortality ratio.

Authors:  O S Miettinen; J D Wang
Journal:  Am J Epidemiol       Date:  1981-07       Impact factor: 4.897

8.  Renovascular disease and hypertension in children with neurofibromatosis.

Authors:  E Fossali; E Signorini; R C Intermite; E Casalini; A Lovaria; M M Maninetti; L N Rossi
Journal:  Pediatr Nephrol       Date:  2000-08       Impact factor: 3.714

9.  Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer.

Authors:  G E Airewele; A J Sigurdson; K J Wiley; B E Frieden; L W Caldarera; V M Riccardi; R A Lewis; M M Chintagumpala; J L Ater; S E Plon; M L Bondy
Journal:  Genet Epidemiol       Date:  2001-01       Impact factor: 2.135

Review 10.  Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis.

Authors:  J M Woodruff
Journal:  Am J Med Genet       Date:  1999-03-26
View more
  142 in total

1.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

2.  The GAP-related domain of neurofibromin attenuates proliferation and downregulates N- and K-Ras activation in Nf1-negative AML cells.

Authors:  Kelly J Morgan; Matthew A Rowley; Stephen M Wiesner; Diane E Hasz; Brian Van Ness; David A Largaespada
Journal:  Leuk Res       Date:  2007-01-12       Impact factor: 3.156

3.  Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation.

Authors:  Seung Tae Baek; Michelle D Tallquist
Journal:  Development       Date:  2012-04-25       Impact factor: 6.868

4.  MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

Authors:  V F Mautner; M Hartmann; L Kluwe; R E Friedrich; C Fünsterer
Journal:  Neuroradiology       Date:  2006-01-24       Impact factor: 2.804

5.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

6.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

Review 7.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

8.  Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I.

Authors:  Marike L D Broekman; Roelof Risselada; Jooyeon Engelen-Lee; Wim G M Spliet; Bon H Verweij
Journal:  Case Rep Med       Date:  2009-12-16

9.  Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice.

Authors:  David C Silvestre; Germán A Gil; Nicolás Tomasini; Daniela F Bussolino; Beatriz L Caputto
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

10.  Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.

Authors:  Christos Kosmas; George Tsakonas; Katerina Evgenidi; Argyris Gassiamis; Lefkothea Savva; Nikolaos Mylonakis; Athanasios Karabelis
Journal:  Cases J       Date:  2009-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.